Across TCGA pan-cancer cohorts, SLITRK6 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLITRK6 data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLITRK6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLITRK6 expression acts as an unfavorable survival marker.

LUAD and HNSC are the cancer types where SLITRK6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.183	0.792	.024	6	view →
HNSC	DFS	Quartile	II,III,IV	0.680	0.893	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: SLITRK6 tumor-vs-normal RNA expression · all SLITRK6 data types